REGO-INTER-EWING-1
Open, not recruiting
Who can enter
Children and young adults with metastatic newly diagnosed Ewing sarcoma
Age: 2 until 50 years old; in the Netherlands, only children and young adults treated at the Princess Máxima Center can participate. In other countries, older patients up to 50 years old can participate.
Goal
Goal
The goal of this study is to determine the optimal dose of the drug regorafenib when taken alongside the standard treatment regimen.
Background
Background
Patients with Ewing sarcoma are treated with courses of chemotherapy. Several drugs are given during the courses of chemotherapy. Regorafenib is a new drug that inhibits cancer cells. We want to give this drug in addition to the standard courses, but the optimal dose is not yet known.
In this study, we want to determine what the best dose is when we give regorafenib alongside standard chemotherapy courses. We are testing different doses for this purpose. We are also looking at side effects and efficacy.
Regorafenib can be taken at home. It can be taken in tablet form and as granules. The drug is approved for adults in the Netherlands. It has also been given to children in smaller studies.
This study is closed for participation.
Last reviewed
Last reviewed
January 8, 2026
Study details
- Study details
Official title
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcomaCancer type
Ewing sarcomaPhase
IbMaximum number of patients
24, of whom 2 are expected to participate in the NetherlandsStart date
April 19, 2024Status
Closed for participationLocal principal investigator
Dr. L.M. HavemanSponsor
Institut Gustave Roussy, ParisApproval
The study of this new treatment has been reviewed by an accredited medical research ethics committee. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO.Trial registry number
ClinialTrials.gov: NCT05830084
The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.